Quest for the right Drug

|

פרווימיס 480 מ"ג טבליות מצופות PREVYMIS 480 MG FILM-COATED TABLETS (LETERMOVIR)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליות מצופות פילם : FILM COATED TABLETS

Pharmacological properties : תכונות פרמקולוגיות

Pharmacodynamic Properties

5.1   Pharmacodynamic properties

Pharmacotherapeutic group: Antivirals for systemic use, direct acting antivirals, ATC code: J05AX18 
Mechanism of action
Letermovir inhibits the CMV DNA terminase complex which is required for cleavage and packaging of viral progeny DNA. Letermovir affects the formation of proper unit length genomes and interferes with virion maturation.

Antiviral activity
The median EC50 value of letermovir against a collection of clinical CMV isolates in a cell-culture model of infection was 2.1 nM (range = 0.7 nM to 6.1 nM, n=74).


Viral resistance
In cell culture
The CMV genes UL51, UL56, and UL89 encode subunits of CMV DNA terminase. CMV mutants with reduced susceptibility to letermovir have been confirmed in cell culture. EC50 values for recombinant CMV mutants expressing the substitutions map to pUL51 (P91S), pUL56 (C25F, S229F, V231A, V231L, V236A, T244K, T244R, L254F, L257F, L257I, F261C, F261L, F261S, Y321C, L328V, M329T, A365S, N368D), and pUL89 (N320H, D344E) were 1.6- to <10-fold higher than those for wild-type reference virus; these substitutions are not likely to be clinically relevant. EC50 values for recombinant CMV mutants expressing pUL56 substitutions N232Y, V236L, V236M, E237D, E237G, L241P, K258E, C325F, C325R, C325W, C325Y, R369G, R369M, R369S and R369T were 10- to 9,300-fold higher than those for the wild-type reference virus; some of these substitutions have been observed in patients who have experienced prophylaxis failure in clinical trials (see below).

In clinical trials
In a Phase 2b trial evaluating letermovir doses of 60, 120, or 240 mg/day or placebo for up to 84 days in 131 HSCT recipients, DNA sequence analysis of a select region of UL56 (amino acids 231 to 369) was performed on samples obtained from 12 letermovir-treated subjects who experienced prophylaxis failure and for whom samples were available for analysis. One subject (who received 60 mg/day) had a letermovir resistant genotypic variant (GV) (V236M).

In a Phase 3 trial (P001), DNA sequence analysis of the entire coding regions of UL56 and UL89 was performed on samples obtained from 40 letermovir-treated subjects in the FAS population who experienced prophylaxis failure and for whom samples were available for analysis. Two subjects had letermovir-resistant GVs detected, both with substitutions mapping to pUL56. One subject had the substitution V236M and the other subject had the substitution E237G. One additional subject, who had detectable CMV DNA at baseline (and was therefore not in the FAS population), had pUL56 substitutions, C325W and R369T, detected after discontinuing letermovir.

Cross-resistance
Cross-resistance is not likely with medicinal products with a different mechanism of action.
Letermovir is fully active against viral populations with substitutions conferring resistance to CMV DNA polymerase inhibitors (ganciclovir, cidofovir, and foscarnet). A panel of recombinant CMV strains with substitutions conferring resistance to letermovir was fully susceptible to cidofovir, foscarnet and ganciclovir with the exception of a recombinant strain with the pUL56 E237G substitution which confers a 2.1-fold reduction in ganciclovir susceptibility relative to wild-type.

Cardiac electrophysiology
The effect of letermovir on doses up to 960 mg given intravenous on the QTc interval was evaluated in a randomised, single-dose, placebo- and active-controlled (moxifloxacin 400 mg oral) 4-period crossover thorough QT trial in 38 healthy subjects. Letermovir does not prolong QTc to any clinically relevant extent following the 960 mg intravenous dose with plasma concentrations approximately 2- fold higher than the 480 mg intravenous dose.


Clinical efficacy and safety

Adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant To evaluate letermovir prophylaxis as a preventive strategy for CMV infection or disease, the efficacy of letermovir was assessed in a multicenter, double-blind, placebo-controlled Phase 3 trial (P001) in adult CMV-seropositive recipients [R+] of an allogeneic HSCT. Subjects were randomised (2:1) to receive either letermovir at a dose of 480 mg once daily adjusted to 240 mg when co-administered with cyclosporine, or placebo. Randomisation was stratified by investigational site and risk (high vs.
low) for CMV reactivation at the time of study entry. Letermovir was initiated after HSCT (Day 0-28 post-transplant) and continued through Week 14 post-transplant. Letermovir was administered either orally or IV; the dose of letermovir was the same regardless of the route of administration. Subjects were monitored through Week 24 post-transplant for the primary efficacy endpoint with continued follow-up through Week 48 post-transplant.

Subjects received CMV DNA monitoring weekly until post-transplant week 14 and then every two weeks until post-transplant week 24, with initiation of standard-of-care CMV pre-emptive therapy if CMV DNAemia was considered clinically significant. Subjects had continued follow-up through Week 48 post-transplant.

Among the 565 treated subjects, 373 subjects received letermovir (including 99 subjects who received at least one intravenous dose) and 192 received placebo (including 48 subjects who received at least one intravenous dose). The median time to starting letermovir was 9 days after transplantation. Thirty- seven percent (37%) of subjects were engrafted at baseline. The median age was 54 years (range: 18 to 78 years); 56 (15.0%) subjects were 65 years of age or older: 58% were male; 82% were White; 10% were Asian; 2% were Black or African; and 7% were Hispanic or Latino. At baseline, 50% of subjects received a myeloablative regimen, 52% were receiving cyclosporine, and 42% were receiving tacrolimus. The most common primary reasons for transplant were acute myeloid leukemia (38%), myeloblastic syndrome (15%), and lymphoma (13%). Twelve percent (12%) of subjects were positive for CMV DNA at baseline.

At baseline, 31% of subjects were at high risk for reactivation as defined by one or more of the following criteria: Human Leukocyte Antigen (HLA)-related (sibling) donor with at least one mismatch at one of the following three HLA-gene loci: HLA-A, -B or –DR, haploidentical donor; unrelated donor with at least one mismatch at one of the following four HLA-gene loci: HLA-A, -B, - C and -DRB1; use of umbilical cord blood as stem cell source; use of ex vivo T-cell-depleted grafts; Grade 2 or greater Graft-Versus-Host Disease (GVHD), requiring systemic corticosteroids.

Primary efficacy endpoint
The primary efficacy endpoint of clinically significant CMV infection in P001 was defined by the incidence of CMV DNAemia warranting anti-CMV pre-emptive therapy (PET) or the occurrence of CMV end-organ disease. The Non-Completer=Failure (NC=F) approach was used, where subjects who discontinued from the study prior to Week 24 post-transplant or had a missing outcome at Week 24 post-transplant were counted as failures.

Letermovir demonstrated superior efficacy over placebo in the analysis of the primary endpoint, as shown in Table 3. The estimated treatment difference of -23.5% was statistically significant (one-sided p-value <0.0001).


Table 3: P001: Efficacy results in HSCT recipients (NC=F Approach, FAS Population) Letermovir             Placebo
(N=325)                (N=170)
Parameter                                                n (%)                  n (%) Primary efficacy endpoint                                122 (37.5)             103 (60.6) (Proportion of subjects who failed prophylaxis by
Week 24)

Reasons for Failures†
Clinically significant CMV infection                     57 (17.5)              71 (41.8) CMV DNAemia warranting anti-CMV PET                     52 (16.0)              68 (40.0) CMV end-organ disease                                    5 (1.5)                3 (1.8) Discontinued from study                                  56 (17.2)              27 (15.9) Missing outcome                                           9 (2.8)                5 (2.9) 
Stratum-adjusted treatment difference (Letermovir-
Placebo)§
Difference (95% CI)                                      -23.5 (-32.5, -14.6) p-value                                                  <0.0001
†
The categories of failure are mutually exclusive and based on the hierarchy of categories in the order listed.
§
95% CIs and p-value for the treatment differences in percent response were calculated using stratum- adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum (high or low risk). A 1-sided p-value ≤0.0249 was used for declaring statistical significance.
FAS=Full analysis set; FAS includes randomised subjects who received at least one dose of study medicine, and excludes subjects with detectable CMV DNA at baseline. Approach to handling missing values: Non-Completer=Failure (NC=F) approach. With NC=F approach, failure was defined as all subjects with clinically significant CMV infection or who prematurely discontinued from the study or had a missing outcome through Week 24 post-transplant visit window.
N = number of subjects in each treatment group.
n (%) = Number (percent) of subjects in each sub-category.
Note: The proportion of subjects with detectable CMV viral DNA on Day 1 that developed clinically significant CMV infection in the letermovir group was 64.6% (31/48) compared to 90.9% (20/22) in the placebo group through Week 24 post-transplant. The estimated difference (95% CI for the difference) was -26.1% (-45.9%, -6.3%), with a nominal one-sided p-value <0.0048.


Factors associated with CMV DNAemia after Week 14 post-transplant among letermovir-treated subjects included high risk for CMV reactivation at baseline, GVHD, use of corticosteroids, and CMV negative donor serostatus.


Figure 1: P001: Kaplan-Meier plot of time to initiation of anti-CMV PET or onset of CMV end- organ disease through Week 24 post-transplant in HSCT recipients (FAS population) 


60

Letermovir vs Placebo
50            Stratified log-rank test, two-sided p-value <0.0001 with CMV DNAemia or disease (%)


44.3%
Cumulative proportion of subjects



41.3%       Placebo

40


30


18.9%
20
Letermovir

10                                                  6.8%



0
Week 0                                     Week 14                      Week 24 
Weeks Post-Transplant


Number of Subjects at Risk
Letermovir                                      325                                          270                         212 Placebo                                         170                                           85                         70 


There were no differences in the incidence of or time to engraftment between the PREVYMIS and placebo groups.

Efficacy consistently favoured letermovir across subgroups including low and high risk for CMV reactivation, conditioning regimens, and concomitant immunosuppressive regimens (see Figure 2).


Figure 2: P001: Forest plot of the proportion of subjects initiating anti-CMV PET or with CMV end-organ disease through Week 24 post-transplant by selected subgroups (NC=F approach, FAS population)



Overall (N=325, 170)

Risk stratum
High Risk (n=102, 45)
Low Risk (n=223, 125)
Stem Cell Source
Peripheral blood (n=241, 117)
Bone marrow (n=72, 43)

Donor mismatch
Matched related (n=108, 58)
Mismatched related (n=52, 18)
Matched unrelated (n=122, 70)
Mismatched unrelated (n=43, 24)

Haploidentical donor
Yes (n=49, 17)
No (n=276, 153)
Conditioning Regimen
Myeloablative (n=154, 85)
Reduced intensity conditioning (n=86, 48)
Non-myeloablative (n=85, 37)

Immunosuppressive Regimen
Cyclosporin A (n=162, 90)
Tacrolimus (n=145, 69)


-70 -60 -50 -40 -30 -20 -10              0     10    20
Favors Letermovir       Favors Placebo
Letermovir - Placebo Difference (%) and 95% C.I.


NC=F, Non-Completer=Failure. With NC=F approach, subjects who discontinued from the study prior to Week 24 post-transplant or had a missing outcome at Week 24 post-transplant were counted as failures.



Pharmacokinetic Properties

5.2     Pharmacokinetic properties

The pharmacokinetics of letermovir have been characterized following administration in healthy subjects and HSCT recipients. Letermovir exposure increased in a greater than dose-proportional manner. The mechanism is likely saturation/autoinhibition of OATP1B1/3.

In healthy subjects, the geometric mean steady-state AUC and Cmax values were 71,500 ng•hr/mL and 13,000 ng/mL, respectively, with 480 mg once daily oral letermovir.

Letermovir reached steady-state in 9 to 10 days with an accumulation ratio of 1.2 for AUC and 1 for Cmax.

In HSCT recipients, letermovir AUC was estimated using population pharmacokinetic analyses using Phase 3 data (see Table 4). Differences in exposure across treatment regimens are not clinically relevant; efficacy was consistent across the range of exposures observed in P001.


Table 4: Letermovir AUC      (ng•hr/mL) values in HSCT Recipients
Treatment Regimen                              Median (90% Prediction Interval)* 

480 mg Oral, no cyclosporine                   34,400 (16,900, 73,700)
240 mg Oral, with cyclosporine                 60,800 (28,700, 122,000)

* Population post-hoc predictions from the population PK analysis using Phase 3 data 

Absorption
Letermovir was absorbed rapidly with a median time to maximum plasma concentration (Tmax) of 1.5 to 3.0 hours and declined in a biphasic manner. In HSCT recipients, bioavailability of letermovir was estimated to be approximately 35% with 480 mg once daily oral letermovir administered without cyclosporine. The inter-individual variability for bioavailability was estimated to be approximately 37%.

Effect of cyclosporine
In HSCT recipients, co-administration of cyclosporine increased plasma concentrations of letermovir due to inhibition of OATP1B. Bioavailability of letermovir was estimated to be approximately 85% with 240 mg once daily oral letermovir co-administered with cyclosporine in patients.
If letermovir is co-administered with cyclosporine, the recommended dose of letermovir is 240 mg once daily (see section 4.2).

Effect of food
In healthy subjects, oral administration of 480 mg single dose of letermovir with a standard high fat and high calorie meal did not have any effect on the overall exposure (AUC) and resulted in approximately 30% increase in peak levels (C max) of letermovir. Letermovir may be administered orally with or without food as has been done in the clinical trials (see section 4.2).

Distribution
Based on population pharmacokinetic analyses, the mean steady-state volume of distribution is estimated to be 45.5 L following intravenous administration in HSCT recipients.

Letermovir is extensively bound (98.2%) to human plasma proteins, independent of the concentration range (3 to 100 mg/L) evaluated, in vitro. Some saturation was observed at lower concentrations.
Blood to plasma partitioning of letermovir is 0.56 and independent of the concentration range (0.1 to 10 mg/L) evaluated in vitro.

In preclinical distribution studies, letermovir is distributed to organs and tissues with the highest concentrations observed in the gastrointestinal tract, bile duct and liver and low concentrations in the brain.

Biotransformation
The majority of letermovir-related components in plasma is unchanged parent (96.6%). No major metabolites are detected in plasma. Letermovir is partly eliminated by glucuronidation mediated by UGT1A1/1A3.

Elimination
The mean apparent terminal half-life for letermovir is approximately 12 hours with 480 mg intravenous letermovir in healthy subjects. The major elimination pathways of letermovir is biliary excretion as well as direct glucuronidation. The process involves the hepatic uptake transporters OATP1B1 and 3 followed by UGT1A1/3 catalysed glucuronidation.

Based on population pharmacokinetic analyses, letermovir steady-state apparent CL is estimated to be 4.84 L/hr following intravenous administration of 480 mg in HSCT recipients. The inter-individual variability for CL is estimated to be 24.6%.


Excretion
After oral administration of radio-labeled letermovir, 93.3% of radioactivity was recovered in faeces.
The majority of letermovir was biliary excreted as unchanged parent with a minor amount (6% of dose) as an acyl-glucuronide metabolite in faeces. The acyl-glucuronide is unstable in faeces. Urinary excretion of letermovir was negligible (<2% of dose).

Pharmacokinetics in special populations

Hepatic impairment
Letermovir unbound AUC was approximately 81%- and 4-fold higher in subjects with moderate (Child-Pugh Class B [CP-B], score of 7-9) and severe (Child-Pugh Class C [CP-C], score of 10-15) hepatic impairment, respectively, compared to healthy subjects. The changes in letermovir exposure in subjects with moderate hepatic impairment are not clinically relevant.

Marked increases in letermovir unbound exposure are anticipated in patients with moderate hepatic impairment combined with moderate or severe renal impairment (see section 4.2).

Renal impairment
Letermovir unbound AUC was approximately 115- and 81% higher in subjects with moderate (eGFR of 31 to 56.8 mL/min/1.73m2) and severe (eGFR of 11.9 to 28.1 mL/min/1.73m2) renal impairment, respectively, compared to healthy subjects. The changes in letermovir exposure due to moderate or severe renal impairment are not considered to be clinically relevant. Subjects with ESRD have not been studied.

Weight
Based on population pharmacokinetic analyses, letermovir AUC is estimated to be 18.7% lower in subjects weighing 80-100 kg compared to subjects weighing 67 kg. This difference is not clinically relevant.

Race
Based on population pharmacokinetic analyses, letermovir AUC is estimated to be 33.2% higher in Asians compared to Whites. This change is not clinically relevant.

Gender
Based on population pharmacokinetic analyses, there is no difference in letermovir pharmacokinetics in females compared to males.

Elderly
Based on population pharmacokinetic analyses, there is no effect of age on letermovir pharmacokinetics. No dose adjustment is required based on age.

פרטי מסגרת הכללה בסל

א. הטיפול בתרופה יינתן לחולה מבוגר שעובר השתלת מח עצם אלוגנאית ויש לו בדיקה סרולוגית חיובית ל CMV (סרו-חיובי ל CMV). ב. הטיפול בתרופה לא יינתן בשילוב עם Valganciclovir.ג. מתן התרופה ייעשה לפי מרשם של מומחה במחלות זיהומיות או מומחה בהמטולוגיה.

מסגרת הכללה בסל

התוויות הכלולות במסגרת הסל

התוויה תאריך הכללה תחום קליני Class Effect מצב מחלה
א. הטיפול בתרופה יינתן לחולה מבוגר שעובר השתלת מח עצם אלוגנאית ויש לו בדיקה סרולוגית חיובית ל CMV (סרו-חיובי ל CMV). ב. הטיפול בתרופה לא יינתן בשילוב עם Valganciclovir. ג. מתן התרופה ייעשה לפי מרשם של מומחה במחלות זיהומיות או מומחה בהמטולוגיה. 03/02/2022 המטולוגיה Allogeneic hematopoietic stem cell
א. הטיפול בתרופה יינתן לחולה מבוגר שעובר השתלת מח עצם אלוגנאית ויש לו בדיקה סרולוגית חיובית ל CMV (סרו-חיובי ל CMV) הנמצא בסיכון גבוה לרה אקטיבציה של CMV. לעניין זה סיכון גבוה לרה-אקטיבציה יוגדר כאחד מאלה: 1. תורם שלילי ל CMV (סרו-נגטיב); 2. השתלה מתורם שאינו מתאים mismatch; 3. השתלה מתורם הפלו haplo-identical; 4. השתלה מתאי אב שמקורם בחבל טבור cord blood; 5. מושתל עם GvHD מדרגה שניה (Grade 2) ומעלה; 6. שימוש ב-ex vivo T-cell–depleted grafts ב. הטיפול בתרופה לא יינתן בשילוב עם Valganciclovir. ג. מתן התרופה ייעשה לפי מרשם של מומחה במחלות זיהומיות או מומחה בהמטולוגיה. 30/01/2020 המטולוגיה Allogeneic hematopoietic stem cell transplant, השתלת מח עצם אלוגנאית
שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 30/01/2020
הגבלות תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת

רישום

166 14 35993 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

26.02.23 - עלון לרופא 14.10.23 - עלון לרופא

עלון מידע לצרכן

07.08.22 - עלון לצרכן ערבית 26.02.23 - עלון לצרכן אנגלית 26.02.23 - עלון לצרכן עברית 14.10.23 - עלון לצרכן אנגלית 14.10.23 - עלון לצרכן עברית 18.11.23 - עלון לצרכן ערבית

לתרופה במאגר משרד הבריאות

פרווימיס 480 מ"ג טבליות מצופות

קישורים נוספים

RxList WebMD Drugs.com